Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
TLDR
An estimate of research and development costs for new therapeutic agents based on publicly available data is provided to reflect the spectrum of products analyzed, the restricted availability of data in the public domain, and differences in underlying assumptions in the cost calculations.Abstract:
Importance The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion. Objective To estimate the research and development investment required to bring a new therapeutic agent to market, using publicly available data. Design and Setting Data were analyzed on new therapeutic agents approved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a new medicine to market. Data were accessed from the US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside published data on clinical trial success rates. Exposures Conduct of preclinical and clinical studies of new therapeutic agents. Main Outcomes and Measures Median and mean research and development spending on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the required rate of return for an investor) of 10.5% per year, with bootstrapped CIs. All amounts were reported in 2018 US dollars. Results The FDA approved 355 new drugs and biologics over the study period. Research and development expenditures were available for 63 (18%) products, developed by 47 different companies. After accounting for the costs of failed trials, the median capitalized research and development investment to bring a new drug to market was estimated at $985.3 million (95% CI, $683.6 million-$1228.9 million), and the mean investment was estimated at $1335.9 million (95% CI, $1042.5 million-$1637.5 million) in the base case analysis. Median estimates by therapeutic area (for areas with ≥5 drugs) ranged from $765.9 million (95% CI, $323.0 million-$1473.5 million) for nervous system agents to $2771.6 million (95% CI, $2051.8 million-$5366.2 million) for antineoplastic and immunomodulating agents. Data were mainly accessible for smaller firms, orphan drugs, products in certain therapeutic areas, first-in-class drugs, therapeutic agents that received accelerated approval, and products approved between 2014 and 2018. Results varied in sensitivity analyses using different estimates of clinical trial success rates, preclinical expenditures, and cost of capital. Conclusions and Relevance This study provides an estimate of research and development costs for new therapeutic agents based on publicly available data. Differences from previous studies may reflect the spectrum of products analyzed, the restricted availability of data in the public domain, and differences in underlying assumptions in the cost calculations.read more
Citations
More filters
Journal ArticleDOI
High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases
TL;DR: A review of the increasing role of HTS in contemporary drug discovery processes, in particular for NDDs, and evaluate the criteria underlying its successful application is presented in this paper.
Posted Content
On the Opportunities and Risks of Foundation Models.
Rishi Bommasani,Drew A. Hudson,Ehsan Adeli,Russ B. Altman,Simran Arora,Sydney von Arx,Michael S. Bernstein,Jeannette Bohg,Antoine Bosselut,Emma Brunskill,Erik Brynjolfsson,Shyamal Buch,Dallas Card,Rodrigo Castellon,Niladri S. Chatterji,Annie Chen,Kathleen Creel,Jared Davis,Dora Demszky,Chris Donahue,Moussa Doumbouya,Esin Durmus,Stefano Ermon,John Etchemendy,Kawin Ethayarajh,Li Fei-Fei,Chelsea Finn,Trevor Gale,Lauren Gillespie,Karan Goel,Noah D. Goodman,Shelby Grossman,Neel Guha,Tatsunori Hashimoto,Peter Henderson,John Hewitt,Daniel E. Ho,Jenny Hong,Kyle Hsu,Jing Huang,Thomas Icard,Saahil Jain,Dan Jurafsky,Pratyusha Kalluri,Siddharth Karamcheti,Geoff Keeling,Fereshte Khani,Omar Khattab,Pang Wei Koh,Mark Krass,Ranjay Krishna,Rohith Kuditipudi,Ananya Kumar,Faisal Ladhak,Mina Lee,Tony Lee,Jure Leskovec,Isabelle Levent,Xiang Lisa Li,Xuechen Li,Tengyu Ma,Ali Ahmad Malik,Christopher D. Manning,Suvir Mirchandani,Eric Mitchell,Zanele Munyikwa,Suraj Nair,Avanika Narayan,Deepak Narayanan,Ben Newman,Allen Nie,Juan Carlos Niebles,Hamed Nilforoshan,Julian Nyarko,Giray Ogut,Laurel Orr,Isabel Papadimitriou,Joon Sung Park,Chris Piech,Eva Portelance,Christopher Potts,Aditi Raghunathan,Rob Reich,Hongyu Ren,Frieda Rong,Yusuf H. Roohani,Camilo Ruiz,Jack Ryan,Christopher Ré,Dorsa Sadigh,Shiori Sagawa,Keshav Santhanam,Andy Shih,Krishnan Srinivasan,Alex Tamkin,Rohan Taori,Armin W. Thomas,Florian Tramèr,Rose E. Wang,William Yang Wang,Bohan Wu,Jiajun Wu,Yuhuai Wu,Sang Michael Xie,Michihiro Yasunaga,Jiaxuan You,Matei Zaharia,Michael Zhang,Tianyi Zhang,Xikun Zhang,Yuhui Zhang,Lucia Zheng,Kaitlyn Zhou,Percy Liang +113 more
TL;DR: The authors provides a thorough account of the opportunities and risks of foundation models, ranging from their capabilities (e.g., language, vision, robotics, reasoning, human interaction) and technical principles(e. g.g. model architectures, training procedures, data, systems, security, evaluation, theory) to their applications.
Journal ArticleDOI
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.
Michael V. Holmes,Tom G. Richardson,Brian A. Ference,Neil M Davies,Neil M Davies,George Davey Smith +5 more
TL;DR: This Review compares and contrast the use of Mendelian randomization to evaluate potential drug targets versus quantitative traits and explains how genetic epidemiological studies can be used to assess the aetiological roles of biomarkers in disease and to prioritize drug targets, including designing their evaluation in clinical trials.
Journal ArticleDOI
Utilizing graph machine learning within drug discovery and development.
Thomas Gaudelet,Ben Day,Arian R. Jamasb,Jyothish Soman,Cristian Regep,Gertrude Liu,Jeremy B. R. Hayter,Richard Vickers,Charles Roberts,Jian Tang,David Roblin,Tom L. Blundell,Michael M. Bronstein,Michael M. Bronstein,Jake P. Taylor-King +14 more
TL;DR: Graph machine learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets as mentioned in this paper.
Journal ArticleDOI
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery
TL;DR: A conceptual framework for understanding the pharmacology of biased allosteric modulators is provided, their therapeutic potential is explored, and strategies for their discovery are discussed.
References
More filters
Posted Content
Methods for the Economic Evaluation of Health Care Programmes
TL;DR: The fourth edition of the Methods for the Economic Evaluation of Health Care Programmes as mentioned in this paper has been thoroughly revised and updated, making it essential reading for anyone commissioning, undertaking, or using economic evaluations in health care, including health service professionals, health economists, and health care decision makers.
Methods for the Economic Evaluation of Health Care Programmes, Second Edition
TL;DR: The second edition of the first edition of this book was published in 1987 as discussed by the authors, and the second edition includes new chapters on collection and analysis of data and on the presentation and use of data.
Journal ArticleDOI
The price of innovation: new estimates of drug development costs
TL;DR: The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms and used to estimate the average pre-tax cost of new drug development.
Journal ArticleDOI
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul,Daniel S. Mytelka,Dunwiddie Christopher T,Charles C. Persinger,Bernard H. Munos,Stacy R. Lindborg,Aaron Leigh Schacht +6 more
TL;DR: A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.
Journal ArticleDOI
Innovation in the pharmaceutical industry: New estimates of R&D costs
TL;DR: The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms and used to estimate the average pre-tax cost of new drug and biologics development.